Centrosome abnormalities are often observed in premalignant lesions and in situ tumors and have been associated with aneuploidy and tumor development. We investigated the associations of 9354 single-nucleotide polymorphisms (SNPs) in 106 centrosomal genes with lung cancer risk by first using the summary data from six published genome-wide association studies (GWASs) of the Transdisciplinary Research in Cancer of the Lung (TRICL) (12 160 cases and 16 838 controls) and then conducted in silico replication in two additional independent lung cancer GWASs of Harvard University (984 cases and 970 controls) and deCODE (1319 cases and 26 380 controls). A total of 44 significant SNPs with false discovery rate (FDR) ≤ 0.05 were mapped to one novel gene FGFR1OP and two previously reported genes (TUBB and BRCA2). After combined the results from TRICL with those from Harvard and deCODE, the most significant association (P combined = 8.032 × 10 −6 ) was with Downloaded from https://academic.oup.com/carcin/article-abstract/37/3/280/2365953 by guest on 26 January 2019
Introduction
Lung cancer represents the number one cancer-related mortality worldwide, with more than 1.6 million cases diagnosed and 1.3 million deaths per year (1) . In the United States, it is the primary cause of deaths from cancers in both men and women, leading to more deaths than from breast, colorectal and prostate cancers all combined. Although lung cancer is commonly considered a disease caused by environmental exposures, genetic factors also play a role in the etiology (2) . Genomic regions at chromosomes 15q25.1 (3, 4) , 5p15.33 (4-6), 6p21.33 (4), 3q28 (4, 7, 8) , 13q13.1 (8) and 22q12.1 (8) have been identified to be associated with lung cancer susceptibility by genome-wide association studies (GWASs) in populations of European descent.
Centrosomes are the pivotal regulating element of cell division and act as a reaction center where the cell cycle key regulating elements assemble and play an important role in cell polarization and ciliogenesis (9, 10) . Recent studies have revealed that deregulation of centrosome-related proteins induce centrosome abnormalities (11) , which in turn result in tumor development through the induction of chromosome instability and aneuploidy (12, 13) . A growing body of evidence has linked centrosome abnormalities to the developments of solid tumors and hematopoietic malignancies (10) , and the underlying mechanisms are now an active area of research (14) (15) (16) .
Centrosome abnormalities and chromosome instability are also frequently observed in human lung cancer (17) . Genes involved in centrosome dysregulation have emerged as the candidate targets to study the mechanism of initiation and progression of lung cancer. In this study, we hypothesized that genetic variants of centrosomal genes are associated with lung cancer risk. To test this hypothesis, we performed a meta-analysis of the association results of SNPs in centrosomal genes from eight lung cancer GWASs from Transdisciplinary Research in Cancer of the Lung (TRICL) and ILCCO, including 14 463 cases and 44 188 controls.
Materials and methods

Study populations
The study populations have been detailed previously (8, 18) . Briefly, this study included six previously reported lung cancer GWASs of from the TRICL, which was built upon the collaborative network of the International Lung Cancer Consortium (ILCCO) (8, 18) 
Genotyping platforms and quality controls
For these GWASs, genotyping was performed using Illumina HumanHap 317, 317+240S, 370Duo, 550, 610 or 1M arrays. Imputation was performed by using data from the 1000 Genomes Project (phase I integrated release 3, March 2012) (21) as reference and IMPUTE2 v2.1.1 (22) , MaCH v1.0 (23) or minimac (version 2012.10.3) (24) software. Poorly imputed SNPs defined as an information score < 0.40 with IMPUTE2 or an r 2 < 0.30 with MaCH were excluded from the final analyses. Standard quality control on samples was performed on all scans, excluding individuals with low call rate (< 90%) and extremely high or low heterozygosity (P < 1.0 × 10 −4 ), as well as all individuals evaluated to be of non-European ancestry (using the HapMap phase II CEU, JPT/CHB and YRI populations as a reference).
Genes and SNPs selection
The centrosomal genes were collected from the Molecular Signatures Database (http://software.broadinstitute.org/gsea/msigdb), which is a collection of annotated gene sets for use with gene set enrichment analysis. Overall, 106 centrosomal genes located on autosomal chromosomes were selected (Supplementary Table 1 , available at Carcinogenesis Online). The genotyped or imputed common SNPs located within 2 kB up-and downstream of centrosomal genes were extracted from the GWAS datasets and the final meta-analysis included 9354 SNPs with genotyping call rate ≥90%, minor allele frequency ≥5%, and Hardy Weinberg Equilibrium exact P ≥ 10 -5 . As previously reported (8, 25) , SNPs from the 1000 Genomes project release Phase 1 integrated release version 3 and filtered with only SNPs showing imputation accuracy > 0.3 were retained. The detailed workflow is shown in Supplementary Figure 1 , available at Carcinogenesis Online.
In silico functional validation
To predict the potential functions of risk-associated SNPs and their highlinkage disequilibrium (LD) (r 2 ≥ 0.60) variants, we used three in silico tools: SNPinfo (26), RegulomeDB (27) and F-SNP (28) . Expression quantitative trait loci (eQTL) analysis was carried out using lymphoblastoid cell data from 1000 Genomes Project (21) European subpopulation (EUR, 373 individuals) (phase I integrated release 3, March 2012).
Statistical methods
For each GWAS, ORs and associated 95% CIs were calculated by unconditional logistic regression using R (v2.6), Stata (v10, State College, Texas, USA) and PLINK (v1.06) (29) software. With the inverse variance method, meta-analysis under fixed and random-effects models was conducted on the results of log-additive model of 9354 SNPs. Cochran's Q statistic to test for heterogeneity and the I 2 statistic to quantify the proportion of the total variation due to heterogeneity were calculated (30) . Fixed effects model was applied when there was no heterogeneity among GWASs (Q-test P > 0.100 and I 2 < 50%); otherwise, random effects model was applied. The false discovery rate (FDR) procedure was employed to control for multiple testing (31) with FDR ≤ 0.050. The correlation between SNPs and corresponding mRNA expression levels was estimated by using a linear regression model. 
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Results
Meta-analysis of the main effects of SNPs in 106 centrosomal genes
The samples sizes of the used GWASs in this study are summarized in Table 1 . In this study, we firstly carried out the analysis within the six TRICL GWASs, which included 12 160 lung cancer case subjects and 16 838 unaffected controls. After stringent quality control, we analyzed 9354 SNPs from 106 centrosomal genes ( Figure 1 ). There are 843 SNPs and 96 SNPs with nominal P < 0.050 and < 0.001 under an additive (per allele) model, respectively; 44 SNPs remained significant at the FDR threshold ≤ 0.050. These top SNPs are mapped to TUBB, FGFR1OP and BRCA2, respectively ( Table 2 ). We removed SNPs that had a high pairwise LD with those in previously reported GWASs (4, 8, 34 ) (TUBB at 6p21.33 and BRCA2 at 13q13.1), and only SNPs mapped to FGFR1OP were included for the additional analyses. The regional association plots demonstrated that SNP rs12212247
showed high LD (r 2 ≥ 0.60) with other 31 SNPs in FGFR1OP, except for rs151606 ( Figure 2 ; Supplementary Table 2, available at Carcinogenesis Online). Finally, two tagSNPs (rs151606 and rs12212247) in FGFR1OP were selected for the further analysis. As shown in Table 3 , both SNPs had a high imputation quality in each dataset.
Of these two SNPs, rs151606 A>T was shown to be associated with an increased risk of lung cancer (OR = 1.12, 95% CI = 1.07-1.17, P = 1.177 × 10 -6 ), while rs12212247 T>C was associated with a decreased risk (OR = 0.93, 95% CI = 0.90-0.97, P = 8.926 × 10 -5 ). There was no heterogeneity observed for these risk estimates in these six GWASs ( Figure 3) .
We sought to expand these findings in another two independent lung cancer GWASs from Harvard University (984 cases and 970 controls) and deCODE (1319 cases and 26 380 controls). When the two studies were combined, rs12212247 and its 31 high LD SNPs within FGFR1OP were found with the same effect direction with a nominal P = 0.039. In addition, the protective effect of SNP rs151606 was insignificant (Table 3; Supplementary Table 3 , available at Carcinogenesis Online). However, when we combined the summary results of all the eight studies, we observed a significant evidence for the association of rs151606 and lung cancer risk (OR = 1.10, 95% CI = 1.05-1.14, P combined = 8.032 × 10 −6 ) and rs12212247 (OR = 0.93, 95% CI = 0.90-0.96, P combined = 9.589 × 10 −6 ) ( Table 3 ; Figure 3 ), given only 9354 SNPs were tested for their associations with lung cancer risk in the present study.
Stratified analyses
Like many other cancers, lung cancer histologic subtypes can have dramatically different clinical behaviors. In the further analyses stratified by histology, only adenocarcinoma (AD) and squamous cell carcinoma (SQ) were included. SNP rs151606 was associated only with the risk of SQ (OR = 1.09, 95% CI = 1.02-1.16, P combined = 0.011), but not with AD (OR = 1.06, 95% CI = 1.00-1.13, P combined = 0.058); the strongest effect of rs12212247 was detected in AD (OR = 0.94, 95%CI = 0.89-0.98, P combined = 0.007), and then in SQ (OR = 0.95, 95%CI = 0.90-1.00, P combined = 0.043) (Figure 3 ).
In silico functional validation
In silico eQTL analysis was performed by using the lymphoblastoid cell lines from 373 individuals of European descendent. The rs151606 genotypes demonstrated significant association with decreased mRNA expression of FGFR1OP in both additive (P trend = 0.022) and recessive models (P trend = 0.031) (Figure 4 ). According to the prediction results of the online tool F-SNP, SNP rs151606 might be associated with mRNA expression by Fixed effect models were used when no heterogeneity was found between studies (Q test P > 0.10 and I 2 < 50.0%); otherwise, random effect models were used. c '+' means positive association and '-' means negative association.
influencing the binding activity of transcriptional factors (i.e. HNF-3b, XFD-2). Although rs12212247 might have an effect on the activity of transcription factor binding site (TFBS) as predicted by SNPinfo and RegulomeDB score of 2b (Supplementary  Table 4 , available at Carcinogenesis Online), which indicated that transcription factor TAF1 binding might be influenced according to the Encyclopedia of DNA Elements (ENCODE) ChIP-Seq data from human A549 cells (35), we did not find any significant association of this SNP with FGFR1OP mRNA expression levels in either model (Figure 4 ).
Discussion
The centrosome is the crucial microtubule-organizing center in animal cells and comprises of a pair of centrioles surrounded by the pericentriolar material (36) . Centrosome deficiencies, including the occurrence of extra centrioles, and increased ability to nucleate microtubules, are common in a high percentage of many tumors. While centrosome deficiencies in cancer may arise as a result of tumorigenesis, early centrosome aberrations may also lead to increased risk of malignancy (37). Our study firstly attempted to systematically examine the effects of genetic variants in the centrosomal genes on lung cancer susceptibility. Notably, we found two potentially functional SNPs in FGFR1OP to be associated with lung cancer risk in the final meta-analysis of 14 463 lung cancer patients and 44 188 control subjects. Our current study is the first to provide an important insight into the association of variants in 6q27 and carcinogenesis, suggesting that FGFR1OP (rs151606 and rs12212247) could represent a novel lung cancer locus in Caucasian populations.
FGFR1OP (fibroblast growth factor receptor 1 oncogene partner) is a centriolar satellite cargo protein, by which centriolar satellites play the role of key mediators of centrosome functions (38) . It has been reported that FGFR1OP is involved in G1/S transition and thus necessary for cell-cycle progression and survival (39) . Two chromosomal translocations, fusing this gene with the FGFR1 and RET genes, have been found in hematopoietic cancers (40, 41) . Published GWASs have identified several SNPs in the nearby region (6q27) of FGFR1OP to be associated with the risk of multiple autoimmune diseases, including Crohn's disease (rs2301436 in FGFR1OP) (42) , Graves' disease (rs9355610 near RNASET2) (43), rheumatoid arthritis (rs3093024 and rs3093023 near CCR6) (44,45) and vitiligo (rs2236313 in RNASET2 and rs6902119 near CCR6) (46, 47) . Recent studies have also suggested a link between autoimmune diseases and some cancers (48) (49) (50) . However, little is known about the association between the genetic variants in FGFR1OP and cancer risk. In this study, we observed that FGFR1OP rs151606 T allele was associated with decreased levels of mRNA expression and increased risk of lung cancer. These results indicate that the association between SNP rs151606 and lung cancer risk might due to its effect on the expression of FGFR1OP, as suggested the eQTL evidence for a role of FGFR1OP in the assembling of mitotic spindle (10, 13, 51) . However, the exact molecular mechanism underlying the associations among lower expression of FGFR1OP on spindle multipolarity, centrosome amplification and lung cancer risk warrants additional investigation.
Except for dysregulation of gene expressions, exposure to environmental risk factors has also been shown to induce centrosome abnormality (52) . Several studies have reported that exposure to chrysotile asbestos fibers, chromate particles, arsenite, and benzo[a]pyrene diol epoxide, which is a carcinogen present in tobacco smoke as well as in environmental pollution, might cause centrosome abnormalities and multipolar spindles in human lung cells (53) (54) (55) (56) (57) . Early occurrence of centrosome alterations have been found in the uninvolved lung tissues adjacent to the tumor of NSCLCs, representing an early event in pulmonary carcinogenesis by increasing chromosome instability (58, 59) . Based on these previous reports and our current findings, analysis of an interaction between SNPs and main environmental risk factors (i.e. smoking status) in future studies might provide novel evidence for the effects of genetic variants in centrosomal genes on lung cancer risk.
Previous studies have identified several genetic variants in centrosomal genes (NIN, TUBG1 and APC) that contributed to breast (60) or pancreatic (61) cancer susceptibility among the Caucasian populations. However, in the present study, we did not find any significance for those SNPs but identified four other SNPs within NIN (rs67977855, rs45558232, rs59096640 and rs4534750) showing moderate associations with lung cancer risk (P ≤ 0.05) based on the six TRICL GWASs results (data not shown). Such inconsistence might due to the heterogeneity among cancers or populations.
There are some potential limitations of the present study. Firstly, the gene-set selection mainly depended on the quality and integrity of curated biological pathways. As the biological understanding of the function of diverse genes in pathways has been steadily improved, the emerging new data on functions of these genes will inevitably expand the currently available lists of 'canonical' pathways. Some important centrosomal genes might be omitted in this study. Considering this, we comprehensively considered multiple centrosomal gene sets and managed to make an all-inclusive listing as possible as we could. Secondly, defining whether a particular SNP is of biological function was limited by the applied in silico tools. To overcome this limitation, we combined the prediction results of multiple bioinformatics tools to explain our data. Thirdly, our eQTL analyses were limited to lymphoblastoid cell lines with publically available data, and gene expression analysis in tissues will give biologically plausible and more convincing results of the effect of those two identified SNPs.
In summary, the present study found significant associations between SNPs in FGFR1OP and lung cancer risk. The results suggested that the SNPs within the centrosomal genes may serve as potential markers to predict lung cancer risk in European populations. Our discoveries shed some new light on the role of centrosome abnormalities in human carcinogenesis. Further validation and functional evaluation of these genetic variants are needed to verify our findings. 
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